Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-based multivalent seasonal influenza vaccine candidates
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
mRNA-based multivalent seasonal influenza vaccine candidates refer to a group of investigational vaccines developed by GSK (formerly in collaboration with CureVac) designed to provide protection against seasonal influenza. These candidates utilize messenger RNA (mRNA) technology encapsulated in lipid nanoparticles (LNPs) to instruct host cells to produce viral hemagglutinin (HA) antigens. By targeting multiple strains of influenza A and B (typically quadrivalent, covering H1N1, H3N2, and two B lineages), these vaccines aim to elicit robust humoral and cellular immune responses. Following a restructuring of their partnership in July 2024, GSK acquired full rights to these candidates, which are currently being evaluated in Phase 2 clinical trials to assess their safety and immunogenicity compared to traditional inactivated influenza vaccines.
- Other names
- GSK mRNA influenza vaccineCureVac/GSK mRNA flu vaccine
02
Targets
BCR (Hemagglutinin-specific B-cell receptor)HA0 (Influenza B virus hemagglutinin)NeuraminidaseT-cell receptor recognizing influenza hemagglutinin peptide-MHC complexesHA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA-based multivalent seasonal influenza vaccine candidates.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-based multivalent seasonal influenza vaccine candidates.